HIGHBuilt-inPipeline
firmonertinib
“10-K Item 1A: 'We currently depend significantly on the success of firmonertinib.'”
AVBP · Concentration risk · 10-K extracted
ArriVent BioPharma (AVBP) concentration risks
Updated
The most significant concentration ArriVent BioPharma discloses is firmonertinib, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: ArriVent BioPharma’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 3 disclosed concentrations
HIGH3
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partySupplier
Chinese third-party manufacturers
“10-K Item 1A: 'We currently rely on Chinese third parties for the manufacture of firmonertinib, ARR-217, and ARR-002 for clinical development'”
HIGHOutside partyCounterparty
exclusive licensors
“10-K Item 1A: 'We heavily rely on our exclusive licenses with our partners to provide us with intellectual property rights to develop and commercialize our product candidates.'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-07-06ArriVent BioPharma's risk profile is dominated by a single-asset structural dependency: the company depends significantly on the success of firmonertinib, meaning its entire near-term value case rests on one clinical and commercial outcome rather than a diversified pipeline. That structural concentration is compounded by two dependency-type exposures on the operational side. Manufacturing for firmonertinib, along with ARR-217 and ARR-002, currently relies on Chinese third parties, concentrating supply-chain execution in a single geography and set of counterparties outside the company's direct control. Separately, the company heavily relies on its exclusive licenses with partners for the intellectual property rights underlying its product candidates, meaning continued access to those rights — not just clinical success — is itself a dependency. None of these three carry disclosed percentage figures, but all are flagged at a high share of the company's risk exposure. The structural firmonertinib dependency is the one most likely to move the investment verdict outright, since it defines whether there is a commercial business at all; the manufacturing and licensing dependencies are narrower but still consequential, since either could impede execution even if the clinical case succeeds.
For the engine’s reasoning on AVBP’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Biotechnology
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| AVBP● | ArriVent BioPharma, Inc. | 3 | 0 | 0 | 3 |
| ACAD | ACADIA Pharmaceuticals Inc. | 2 | 0 | 0 | 2 |
| ABUS | Arbutus Biopharma Corporation | 1 | 1 | 0 | 2 |
| ABSI | Absci Corporation | 1 | 0 | 0 | 1 |
| ABCL | AbCellera Biologics Inc. | 0 | 0 | 0 | 0 |
| ACHV | Achieve Life Sciences, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.